All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Adjuvant Atezolizumab and Bevacizumab Delays Recurrence in Early-Stage HCC

May 10th 2023

Ahmed O. Kaseb, MD, discusses how the previous approval of atezolizumab and bevacizumab in hepatocellular carcinoma provided the impetus for the IMBrave050 study, how data from this study could support the regimen’s approval in the adjuvant setting, and how this approval could substantially improve the treatment landscape for early-stage disease.

Ivosidenib Wins European Approval for IDH1-mutated AML and Cholangiocarcinoma

May 10th 2023

The European Commission has approved ivosidenib tablets in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy, and as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who received at least 1 prior line of systemic therapy.

Extended Administration of Adjuvant Anatrozole Prolongs DFS in Postmenopausal HR+ Breast Cancer

May 10th 2023

Treatment with adjuvant anastrozole over a 10-year period remained tolerable and increased disease-free survival rates in postmenopausal women with hormone receptor–positive breast cancer, according to data from the phase 3 AERAS trial.

Fox Chase Cancer Center Welcomes Dr. Abigail T. Berman

May 10th 2023

Fox Chase Cancer Center is pleased to announce the hiring of Abigail T. Berman, MD, MSCE, as an assistant professor in the Department of Radiation Oncology.

FDA Grants Orphan Drug Status to RAD 301 for Imaging of Pancreatic Ductal Adenocarcinoma

May 10th 2023

The FDA has granted an orphan drug designation to RAD 301 for the imaging of patients with pancreatic ductal adenocarcinoma.

New Research Results Spotlight Rare Molecular Subtypes in NSCLC

May 10th 2023

Although molecularly targeted therapies have transformed the treatment paradigm for NSCLC, the kaleidoscope of genomic alterations that affects subsets of patients is straining the limits of current diagnostic and clinical discovery approaches.

Frontline Avelumab Maintenance Provides Prolonged Survival Benefit in Urothelial Carcinoma

May 10th 2023

Shilpa Gupta, MD, discussed the significance of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer, updated data on the use of avelumab maintenance therapy following first-line chemotherapy in this population, and how this research could better inform patient-provider conversations about this option in the clinic.

Unpacking the Implications of CAR T-cell Therapy for Patients With Multiple Myeloma

May 9th 2023

Abhinav Deol, MD, gives insight on CAR T-cell therapy’s future role in the treatment landscape for multiple myeloma and what needs to be done to push the needle forward.

Short-term QOL Scores Lower in Non-Hispanic Black Patients With Prostate Cancer After Radical Prostatectomy

May 9th 2023

Mara Koelker, MD, discusses the rationale of evaluating racial differences in QOL for patients with prostate cancer and ways to address these short-term disparities in a real-world setting.

Continued Development of Targeted Therapies Aims to Address Unmet Needs in CRC

May 9th 2023

John L. Marshall, MD, discusses the identification of targetable subsets of patients with advanced CRC, unmet needs that remain to be addressed for patients with advanced CRC, and the continued need for a multidisciplinary approach in treating patients across the gastrointestinal cancer spectrum.

FDA Grants Fast Track Designation to ACR-368 in Platinum-resistant Ovarian Cancer and Endometrial Cancer

May 9th 2023

The FDA has granted fast track designations to ACR-368 monotherapy for the treatment of patients with platinum-resistant ovarian cancer and endometrial cancer who are positive for predicted sensitivity to the agent using Acrivon Therapeutics’ OncoSignature® test.

International Study Shows Many Younger Women with Breast Cancer Can Safely Have a Baby

May 9th 2023

A new study published today in the New England Journal of Medicine found that for young women with hormone receptor-positive breast cancer, pausing endocrine therapy to pursue a pregnancy did not raise the short-term risk that the disease will recur.

MANIFEST-2 Study of Pelabresib Plus Ruxolitinib Completes Enrollment in Myelofibrosis

May 9th 2023

Enrollment to the phase 3 MANIFEST-2 trial, which is examining the safety and efficacy of pelabresib plus ruxolitinib vs ruxolitinib alone in patients with JAK inhibitor–naïve myelofibrosis, has completed and topline findings are anticipated by the end of 2023.

Decentralization Efforts Could Engage Community Oncologists

May 9th 2023

As more treatment options enter the oncology landscape, access to these life-changing medicines has become a paramount concern.

REGN5459 Demonstrates Early Promise in Heavily Pretreated Multiple Myeloma

May 9th 2023

Attaya Suvannasankha, MD, discusses the unique mechanism of action of REGN5459, the early efficacy and safety of the immunotherapy in heavily pretreated patients with relapsed/refractory multiple myeloma, and opportunities for further exploration.

China Approves Zanubrutinib in Previously Untreated CLL/SLL and Waldenström Macroglobulinemia

May 8th 2023

China’s National Medical Products Administration has approved 2 supplemental new drug applications of zanubrutinib for use in treatment-naïve adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenström macroglobulinemia.

Venetoclax Plus Lenalidomide/Rituximab Regimen Delivers Safety, Efficacy in Untreated Mantle Cell Lymphoma

May 8th 2023

The addition of venetoclax to lenalidomide and rituximab produced early evidence of clinical efficacy with a tolerable safety profile in previously untreated patients with mantle cell lymphoma.

Interval Cytoreductive Surgery After Chemo Boosts Survival in Stage IV Epithelial Ovarian Cancer

May 8th 2023

Liat Hogen, MD, FRCSC, discussed the potential benefit for cytoreductive surgery in patients with initially unresectable stage IV epithelial ovarian cancer and the implications of findings from this retrospective analysis on future clinical decisions.

GD2-CART01 Elicits Clinical Activity, Tolerability in Pediatric R/R Neuroblastoma

May 8th 2023

The investigational CAR T-cell therapy GD2-CART01 showed preliminary antitumor activity and safety in pediatric patients with relapsed or refractory high-risk neuroblastoma, according to data from a phase 1/2 trial.

Sintilimab Plus Chemo With or Without IBI305 Provides PFS Benefit in EGFR TKI–Pretreated EGFR+ NSCLC

May 8th 2023

The combination of sintilimab and chemotherapy with or without the bevacizumab biosimilar IBI305 produced a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with EGFR-mutated, nonsquamous non–small cell lung cancer who progressed after treatment with an EGFR TKI.